海思科：HSK47977片获国家药品监督管理局受理

Core Viewpoint - The company has received an acceptance notification from the National Medical Products Administration for its IND application of HSK47977, a new oral small molecule anti-tumor drug aimed at treating lymphoma, marking a significant step in its drug development pipeline [1] Group 1 - HSK47977 is a self-developed drug with no other drugs targeting the same pathway currently in clinical stages globally [1] - Preclinical studies show that HSK47977 exhibits significant proliferation inhibition on human lymphoma cell lines in vitro and effectively suppresses tumor growth in in vivo xenograft models [1] - The drug demonstrates strong target selectivity and an ideal safety window, potentially providing new treatment options for lymphoma patients [1]